Company record · CVKD · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc.'s interim chief financial officer on the record is John P. Sharp, effective June 25, 2026, per the filing record.
The record holds 2 verified CFO changes for Cadrenal Therapeutics, Inc. from Form 8-K filings, filed between June 3, 2026 and June 29, 2026 and the CFO signature on its 10-K filed March 31, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled (interim) |
|---|---|
| Officer | John P. Sharp |
| Title as printed | Interim Chief Financial Officer |
| Basis | Latest move: interim, 8-K filed June 29, 2026 |
Seat timeline
3Every verified record for this seat, newest first, dated as the filing states it.
2026-06-29Interim
Cadrenal Therapeutics, Inc. names John P. Sharp interim CFOeffective June 25, 2026 · 8-K filed June 29, 2026 · sec.gov, Item 5.02
2026-06-03Interim
Cadrenal Therapeutics, Inc. names Quang X. Pham interim CFOeffective May 28, 2026 · 8-K filed June 3, 2026 · sec.gov, Item 5.02
2026-03-3110-K signature
Matthew Szot signed the annual report as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
10-K filed March 31, 2026 · sec.gov
“/s/ Matthew Szot Chief Financial Officer (Principal Financial Officer March 31, 2026 Matthew Szot and Principal Accounting Officer)”
Company
| Ticker | CVKD |
|---|---|
| SEC CIK | 0001937993 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-08-03 also names Matthew Szot alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-09-29, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
Faeth Therapeutics, Inc.SNSE
CFO: Brian Stephenson · effective June 13, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.